The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new ...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine ...

A New Orleans-based biotech company has developed a breakthrough non-opioid pain medication, which is backed by funding from Ochsner Ventures, the investment arm of Ochsner Health, and from Gulf South ...

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ — Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to ...

This meeting will serve as a kick-off for the National Academies consensus study Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary Biotechnology. This me ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

Edesa Biotech ( (EDSA)) has shared an announcement. Edesa Biotech reported its fiscal year 2025 results, highlighting significant progress in its dermatology and respiratory programs. The company ...

The National Academies of Sciences, Engineering, and Medicine will convene an ad hoc study Committee on Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary ...

By Oncolytics Biotech® Inc. Feb 19, 2025 Feb 19, 2025Updated Feb 19, 2025 Oncolytics Biotech Inc Logo By Oncolytics Biotech® Inc. Regulatory progress in pancreatic cancer and recent clinical data ...